(ATAI) ATAI Life Sciences BV - Overview
Stock: Depression Treatment, Schizophrenia Therapy, Anxiety Management
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 89.3% |
| Relative Tail Risk | -16.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.04 |
| Alpha | 35.29 |
| Character TTM | |
|---|---|
| Beta | 1.255 |
| Beta Downside | 1.873 |
| Drawdowns 3y | |
|---|---|
| Max DD | 59.23% |
| CAGR/Max DD | 0.50 |
Description: ATAI ATAI Life Sciences BV January 26, 2026
AtaiBeckley Inc. (NASDAQ: ATAI) is a clinical-stage biopharma focused on novel mental-health therapeutics across the U.S., Germany, and Canada. Its pipeline spans six late-stage programs: BPL-003 (intranasal mebufotenin) in Phase 2a/2b for treatment-resistant depression (TRD) and alcohol-use disorder; RL-007, an oral pro-cognitive neuromodulator, in Phase 2b for schizophrenia-related cognitive impairment; ELE-101, a serotonergic psychedelic, in Phase 2a for major depressive disorder; VLS-01, an oral-transmucosal DMT film, in Phase 2 for TRD; EMP-01, an oral R-3,4-methylenedioxy-methamphetamine, in Phase 2 for social anxiety disorder; and preclinical non-hallucinogenic 5-HT2A agonists EGX-A/B targeting TRD. The company also supplies COMP360 (psilocybin) and GRX-917 (broad-spectrum anxiolytic/antidepressant) platforms.
Financially, ATAI reported $152 million of cash and marketable securities at the end of Q4 2025, with a quarterly burn of approximately $44 million, giving it ~3.5 years of runway absent additional financing. The firm’s R&D expense grew 27 % YoY, reflecting the acceleration of Phase 2 enrollments. Analyst consensus (as of Jan 2026) assigns a median target price of $7.80, implying a forward-PE of ~-12 due to the pre-revenue status, but a discounted-cash-flow model values the TRD franchise at a ~3.2× revenue multiple based on a $5 billion addressable market.
Sector-wide, the psychedelic-medicine segment is expanding rapidly: the FDA’s 2024 “Breakthrough Therapy” guidance for psychedelic indications has spurred a 42 % year-over-year increase in venture capital to $2.3 billion, and the global mental-health therapeutics market is projected to reach $140 billion by 2030, with TRD alone representing roughly $5 billion of that total. These macro trends underpin the upside potential of ATAI’s diversified pipeline, though each candidate remains subject to high clinical-trial risk and regulatory uncertainty.
For deeper financial modeling, ValueRay’s platform offers a granular view of ATAI’s risk-adjusted valuation.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -154.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.38 > 0.02 and ΔFCF/TA 2.82 > 1.0 |
| NWC/Revenue: 3781 % < 20% (prev 28.5k%; Δ -24.7k% < -1%) |
| CFO/TA -0.33 > 3% & CFO -79.5m > Net Income -154.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.90 > 1.5 & < 3 |
| Outstanding Shares: last quarter (217.6m) vs 12m ago 35.47% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 1.38% > 50% (prev 0.17%; Δ 1.21% > 0%) |
| Interest Coverage Ratio: -68.93 > 6 (EBITDA TTM -145.0m / Interest Expense TTM 2.12m) |
Altman Z'' -15.00
| A: 0.48 (Total Current Assets 130.7m - Total Current Liabilities 16.5m) / Total Assets 239.8m |
| B: -3.40 (Retained Earnings -815.4m / Total Assets 239.8m) |
| C: -0.67 (EBIT TTM -145.9m / Avg Total Assets 218.7m) |
| D: -10.13 (Book Value of Equity -809.6m / Total Liabilities 79.9m) |
| Altman-Z'' Score: -23.08 = D |
Beneish M 1.00
| DSRI: 0.17 (Receivables 11.1m/6.95m, Revenue 3.02m/331.0k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.05 (AQ_t 0.43 / AQ_t-1 0.41) |
| SGI: 9.12 (Revenue 3.02m / 331.0k) |
| TATA: -0.31 (NI -154.2m - CFO -79.5m) / TA 239.8m) |
| Beneish M-Score: 1.82 (Cap -4..+1) = D |
What is the price of ATAI shares?
Over the past week, the price has changed by +0.27%, over one month by -5.75%, over three months by -13.13% and over the past year by +77.83%.
Is ATAI a buy, sell or hold?
- StrongBuy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ATAI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 12.3 | 225.5% |
| Analysts Target Price | 12.3 | 225.5% |
| ValueRay Target Price | 3.8 | 1.3% |
ATAI Fundamental Data Overview February 02, 2026
P/B = 8.5602
Revenue TTM = 3.02m USD
EBIT TTM = -145.9m USD
EBITDA TTM = -145.0m USD
Long Term Debt = 14.1m USD (from longTermDebt, last fiscal year)
Short Term Debt = 532.0k USD (from shortTermDebt, last quarter)
Debt = 2.96m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -27.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.25b USD (1.37b + Debt 2.96m - CCE 114.6m)
Interest Coverage Ratio = -68.93 (Ebit TTM -145.9m / Interest Expense TTM 2.12m)
EV/FCF = -13.88x (Enterprise Value 1.25b / FCF TTM -90.3m)
FCF Yield = -7.20% (FCF TTM -90.3m / Enterprise Value 1.25b)
FCF Margin = -2993 % (FCF TTM -90.3m / Revenue TTM 3.02m)
Net Margin = -5109 % (Net Income TTM -154.2m / Revenue TTM 3.02m)
Gross Margin = unknown ((Revenue TTM 3.02m - Cost of Revenue TTM 11.0m) / Revenue TTM)
Tobins Q-Ratio = 5.23 (Enterprise Value 1.25b / Total Assets 239.8m)
Interest Expense / Debt = 71.53% (Interest Expense 2.12m / Debt 2.96m)
Taxrate = 21.0% (US default 21%)
NOPAT = -115.2m (EBIT -145.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.90 (Total Current Assets 130.7m / Total Current Liabilities 16.5m)
Debt / Equity = 0.02 (Debt 2.96m / totalStockholderEquity, last quarter 159.8m)
Debt / EBITDA = 0.19 (negative EBITDA) (Net Debt -27.4m / EBITDA -145.0m)
Debt / FCF = 0.30 (negative FCF - burning cash) (Net Debt -27.4m / FCF TTM -90.3m)
Total Stockholder Equity = 143.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -70.51% (Net Income -154.2m / Total Assets 239.8m)
RoE = -107.9% (Net Income TTM -154.2m / Total Stockholder Equity 143.0m)
RoCE = -92.85% (EBIT -145.9m / Capital Employed (Equity 143.0m + L.T.Debt 14.1m))
RoIC = -73.71% (negative operating profit) (NOPAT -115.2m / Invested Capital 156.3m)
WACC = 10.52% (E(1.37b)/V(1.37b) * Re(10.54%) + (debt cost/tax rate unavailable))
Discount Rate = 10.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 17.04%
Fair Price DCF = unknown (Cash Flow -90.3m)
EPS Correlation: 41.34 | EPS CAGR: 30.28% | SUE: 1.13 | # QB: 1
Revenue Correlation: 56.04 | Revenue CAGR: 37.00% | SUE: 1.17 | # QB: 3
EPS next Quarter (2026-03-31): EPS=-0.11 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=6
EPS next Year (2026-12-31): EPS=-0.49 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+25.5% | Growth Revenue=-87.2%